
Prediction
Science Policy
Which research areas will gain the most funding in 2026?
-
MiroThinker
MiroMind Deep Analysis
Verification
Sources
MiroMind Deep Analysis
7
sources
Multi-cycle verification
Deep Reasoning
Recent 2025–2026 budget data, R&D trend reports, and grant-program focus areas point to a convergence around a few themes: AI as horizontal infrastructure, health and biomedicine, climate/energy transition, cybersecurity, and "real-world risk" fields like extreme-weather forecasting and adaptation. These themes appear consistently in government appropriations, private venture flows, and strategic outlooks.
Key areas likely to gain the most funding
AI for science, health, and industry (""AI for X"")
A 2026 research trends review highlights ""Artificial intelligence for science"" as a top area, noting that AI is planned as a routine part of ""everyday research work in any field"" by 2026[1].
In biopharma, a global R&D analysis shows AI‑enabled discovery and development now embedded across discovery, clinical planning, operations, portfolio decisions, and regulatory processes; AI-driven programs are associated with higher success rates and are a major focus of new investment[2].
VC and startup data show AI platforms and infra capturing a disproportionate share of new capital across sectors (AI startup fundraising and AI energy/digital infra both growing rapidly).
Biomedicine, medicine, and life sciences (including oncology and immunology)
U.S. National Institutes of Health (NIH) funding rises to about $48.7 billion in FY2026, an increase over 2025, with ARPA‑H preserved at $1.5B for high‑risk, high‑reward health research[3].
A global R&D report notes robust pipelines: ~79 novel active substance (NAS) launches in 2025 and an expectation of 70–80 annually over the next five years, reflecting sustained upstream funding across multiple therapeutic areas[2].
Oncology and immunology retain heavy late-stage trial activity (Phase II/III trials up even as total oncology trial starts dip), indicating concentrated funding on high-value programs rather than volume[2].
Climate, energy transition, and climate-tech
Major 2026 investment-research themes project global clean energy infrastructure investment surpassing $2 trillion in 2026, with strong momentum in grid modernization, renewables, and storage[4].
Climate adaptation spending is much smaller (<$100B historically) but flagged as a high‑priority growth area for new capital because of escalating physical climate risk and large financing gaps[4].
Climate-tech industry reports highlight rising capital into batteries, grid technologies, and food/ag-tech; public R&D budgets also emphasize low‑carbon technologies and transition infrastructure.
Cybersecurity and data/privacy
Cyber is singled out as one of the most ""pressing areas for research"" due to growing data volumes and AI‑related vulnerabilities[1].
The U.S. Department of Defense's FY2026 cyberspace activities budget requests around $15.1B, including $611.9M specifically for cyber R&D, a 4.1% increase over the prior year[5].
Global cyber-outlook work indicates that 80–90% of surveyed organizations see AI-related vulnerabilities as the fastest-growing risk, driving both public and private investment into security tooling, architectures, and research.
Energy systems and extreme-weather / climate forecasting
Research priorities include ""energy and transition technologies"" and ""climate, weather and forecasting extreme events,"" driven by rising electricity demand, nuclear and alternative energy roles, and the need to manage extreme events under climate change[1].
These areas sit at the intersection of climate, national security, and infrastructure policy, attracting funding from energy ministries, defense budgets, and disaster‑risk agencies.
Biotech platforms and therapeutics discovery
A 2026 biotech funding analysis shows disclosed equity funding jumping from about $6.8B (2024) to $17.3B (2025), with 2026 year‑to‑date activity still strong and Therapeutics Discovery Platforms accounting for ~89% of capital and 85% of deals[6].
This reflects sustained investor preference for platform plays (e.g., gene-editing platforms, discovery engines) that can spin out multiple assets, often tightly coupled with AI.
Evidence and cross‑checks
Public R&D budgets: U.S. federal research appropriations for 2026 preserve or increase funding for NIH, NSF ($8.75B), and DOE Office of Science ($8.4B), with explicit emphasis on health, basic science, and advanced computing/energy[3].
Private capital: Venture and life‑science deal data show strong flows into AI/ML, healthcare, biotech, and climate tech, with life‑science total deal value up ~47% YoY in 2025 and optimism continuing in 2026[7].
Strategic research & investment outlooks: Morgan Stanley, JPMorgan, and others converge on AI/energy, climate adaptation, circular economy, and biodiversity as top capital‑allocation themes for 2026 and beyond[4][7].
Thematic research commentary: 2026 academic and policy analyses repeatedly list AI for science, biomedicine, cybersecurity, energy, and climate as ""most relevant"" or highest-priority areas for grants and institutional support[1][2].
Counterarguments and caveats
Macrofiscal pressure: U.S. and European deficits and political fights over spending can produce volatility in year‑to‑year grant counts even when top‑line budgets rise; some agencies are awarding fewer, larger grants[2][3].
Regional variation: China and some emerging markets may skew more toward applied industrial R&D (manufacturing, telecoms, green industry) vs. U.S./EU focus on health and climate.
Over‑concentration risk: Very crowded themes (e.g., generic ""AI for X"") may see lower marginal funding per project as competition intensifies.
Implications
Researchers and institutions with credible programs in AI-for-science, biomedicine, climate/energy, cybersecurity, and biotech platforms are best positioned to win 2026 funding.
Cross‑disciplinary work that combines these (e.g., AI‑enabled climate modeling, AI‑powered drug discovery, secure AI systems) is especially attractive to both public and private capital.
Fields outside these clusters can still secure funding, but often by aligning with these macro themes (e.g., social science of climate adaptation, ethics and governance of AI).
MiroMind Reasoning Summary
I gave most weight to concrete 2026 budget numbers, large‑scale R&D trend reports, and cross‑institutional outlooks that explicitly identify priority sectors. Multiple independent sources converged on AI, health/biomedicine, climate/energy, cybersecurity, and biotech platforms, with both public appropriations and private capital supporting these themes. Macrofiscal and regional caveats may modulate funding levels, but are unlikely to change the relative ranking of these areas in 2026.
Deep Research
7
Reasoning Steps
Verification
3
Cycles Cross-checked
Confidence Level
High
MiroMind Deep Analysis
7
sources
Multi-cycle verification
Deep Reasoning
Recent 2025–2026 budget data, R&D trend reports, and grant-program focus areas point to a convergence around a few themes: AI as horizontal infrastructure, health and biomedicine, climate/energy transition, cybersecurity, and "real-world risk" fields like extreme-weather forecasting and adaptation. These themes appear consistently in government appropriations, private venture flows, and strategic outlooks.
Key areas likely to gain the most funding
AI for science, health, and industry (""AI for X"")
A 2026 research trends review highlights ""Artificial intelligence for science"" as a top area, noting that AI is planned as a routine part of ""everyday research work in any field"" by 2026[1].
In biopharma, a global R&D analysis shows AI‑enabled discovery and development now embedded across discovery, clinical planning, operations, portfolio decisions, and regulatory processes; AI-driven programs are associated with higher success rates and are a major focus of new investment[2].
VC and startup data show AI platforms and infra capturing a disproportionate share of new capital across sectors (AI startup fundraising and AI energy/digital infra both growing rapidly).
Biomedicine, medicine, and life sciences (including oncology and immunology)
U.S. National Institutes of Health (NIH) funding rises to about $48.7 billion in FY2026, an increase over 2025, with ARPA‑H preserved at $1.5B for high‑risk, high‑reward health research[3].
A global R&D report notes robust pipelines: ~79 novel active substance (NAS) launches in 2025 and an expectation of 70–80 annually over the next five years, reflecting sustained upstream funding across multiple therapeutic areas[2].
Oncology and immunology retain heavy late-stage trial activity (Phase II/III trials up even as total oncology trial starts dip), indicating concentrated funding on high-value programs rather than volume[2].
Climate, energy transition, and climate-tech
Major 2026 investment-research themes project global clean energy infrastructure investment surpassing $2 trillion in 2026, with strong momentum in grid modernization, renewables, and storage[4].
Climate adaptation spending is much smaller (<$100B historically) but flagged as a high‑priority growth area for new capital because of escalating physical climate risk and large financing gaps[4].
Climate-tech industry reports highlight rising capital into batteries, grid technologies, and food/ag-tech; public R&D budgets also emphasize low‑carbon technologies and transition infrastructure.
Cybersecurity and data/privacy
Cyber is singled out as one of the most ""pressing areas for research"" due to growing data volumes and AI‑related vulnerabilities[1].
The U.S. Department of Defense's FY2026 cyberspace activities budget requests around $15.1B, including $611.9M specifically for cyber R&D, a 4.1% increase over the prior year[5].
Global cyber-outlook work indicates that 80–90% of surveyed organizations see AI-related vulnerabilities as the fastest-growing risk, driving both public and private investment into security tooling, architectures, and research.
Energy systems and extreme-weather / climate forecasting
Research priorities include ""energy and transition technologies"" and ""climate, weather and forecasting extreme events,"" driven by rising electricity demand, nuclear and alternative energy roles, and the need to manage extreme events under climate change[1].
These areas sit at the intersection of climate, national security, and infrastructure policy, attracting funding from energy ministries, defense budgets, and disaster‑risk agencies.
Biotech platforms and therapeutics discovery
A 2026 biotech funding analysis shows disclosed equity funding jumping from about $6.8B (2024) to $17.3B (2025), with 2026 year‑to‑date activity still strong and Therapeutics Discovery Platforms accounting for ~89% of capital and 85% of deals[6].
This reflects sustained investor preference for platform plays (e.g., gene-editing platforms, discovery engines) that can spin out multiple assets, often tightly coupled with AI.
Evidence and cross‑checks
Public R&D budgets: U.S. federal research appropriations for 2026 preserve or increase funding for NIH, NSF ($8.75B), and DOE Office of Science ($8.4B), with explicit emphasis on health, basic science, and advanced computing/energy[3].
Private capital: Venture and life‑science deal data show strong flows into AI/ML, healthcare, biotech, and climate tech, with life‑science total deal value up ~47% YoY in 2025 and optimism continuing in 2026[7].
Strategic research & investment outlooks: Morgan Stanley, JPMorgan, and others converge on AI/energy, climate adaptation, circular economy, and biodiversity as top capital‑allocation themes for 2026 and beyond[4][7].
Thematic research commentary: 2026 academic and policy analyses repeatedly list AI for science, biomedicine, cybersecurity, energy, and climate as ""most relevant"" or highest-priority areas for grants and institutional support[1][2].
Counterarguments and caveats
Macrofiscal pressure: U.S. and European deficits and political fights over spending can produce volatility in year‑to‑year grant counts even when top‑line budgets rise; some agencies are awarding fewer, larger grants[2][3].
Regional variation: China and some emerging markets may skew more toward applied industrial R&D (manufacturing, telecoms, green industry) vs. U.S./EU focus on health and climate.
Over‑concentration risk: Very crowded themes (e.g., generic ""AI for X"") may see lower marginal funding per project as competition intensifies.
Implications
Researchers and institutions with credible programs in AI-for-science, biomedicine, climate/energy, cybersecurity, and biotech platforms are best positioned to win 2026 funding.
Cross‑disciplinary work that combines these (e.g., AI‑enabled climate modeling, AI‑powered drug discovery, secure AI systems) is especially attractive to both public and private capital.
Fields outside these clusters can still secure funding, but often by aligning with these macro themes (e.g., social science of climate adaptation, ethics and governance of AI).
MiroMind Reasoning Summary
I gave most weight to concrete 2026 budget numbers, large‑scale R&D trend reports, and cross‑institutional outlooks that explicitly identify priority sectors. Multiple independent sources converged on AI, health/biomedicine, climate/energy, cybersecurity, and biotech platforms, with both public appropriations and private capital supporting these themes. Macrofiscal and regional caveats may modulate funding levels, but are unlikely to change the relative ranking of these areas in 2026.
Deep Research
7
Reasoning Steps
Verification
3
Cycles Cross-checked
Confidence Level
High
MiroMind Verification Process
1
Compared public FY2026 budgets (NIH, NSF, DOE, DOD cyber) to 2025 levels.
Verified
2
Cross‑checked with global R&D and life‑science deal trend reports for private capital patterns.
Verified
3
Validated thematic claims with independent strategy/outlook pieces (Morgan Stanley, Biocom) focusing on 2026 priorities.
Verified
Sources
[1] Trending research areas: what will be popular in 2026?, SPUBL, 2026. https://spubl.com.ua/en/blog/trending-research-areas-what-will-be-popular-in-2026
[2] Global R&D Trends 2026, IQVIA Institute, Mar 25 2026. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026
[3] FY2026 research appropriations battle: NIH, NSF, DOE, GrantedAI, Mar 22 2026. https://grantedai.com/blog/fy2026-research-appropriations-battle-nih-nsf-doe-grant-strategy-2026
[4] Navigating 2026: Climate, AI, and Economic Shifts, Morgan Stanley IM/Calvert, Jan 14 2026. https://www.morganstanley.com/im/en-us/individual-investor/insights/articles/2026-research-themes.html
[5] FY2026 Department of Defense Cyber Budget Request, CRS IN12616, Nov 24 2025. https://www.congress.gov/crs-product/IN12616
[6] Biotechnology market funding trends 2026, New Market Pitch, May 4 2026. https://newmarketpitch.com/blogs/news/biotech-funding-trends
[7] Optimism Returns to Life Science Funding and Partnerships in 2026, Biocom, Mar 24 2026. https://www.biocom.org/lifelines-article/insights/optimism-returns-to-life-science-in-2026/
Ask MiroMind
Deep Research
Predict
Verify
MiroMind reasons across dozens of sources and delivers answers with a full evidence trail.
Explore more topics
All
Law
Public Health
Research
Technology
Medicine
Finance
Science Policy




